The Enterprise Value as of November 2024 (TTM) for Kura Oncology, Inc. (KURA) is 807.00M

According to Kura Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 807.00M. This represents a change of -49.35% compared to the average of 1.59B of the last 4 quarters.

Kura Oncology, Inc. (KURA) Historical Enterprise Value (quarterly & annually)

How has KURA Enterprise Value performed in the past?

The mean historical Enterprise Value of Kura Oncology, Inc. over the last ten years is 566.88M. The current 807.00M Enterprise Value has changed 14.14% with respect to the historical average. Over the past ten years (40 quarters), KURA's Enterprise Value was at its highest in in the June 2024 quarter at 1.81B. The Enterprise Value was at its lowest in in the March 2015 quarter at -5811000.00.

Kura Oncology, Inc. (KURA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Kura Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kura Oncology, Inc. (KURA) Average Enterprise Value

How has KURA Enterprise Value performed in the past?

The current Enterprise Value of Kura Oncology, Inc. (KURA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Kura Oncology, Inc. (KURA) Enterprise Value vs. Peers

How is KURA’s Enterprise Value compared to its peers?

Kura Oncology, Inc.’s Enterprise Value is less than Protagonist Therapeutics, Inc. (2.65B), less than Merus N.V. (2.68B), less than Replimune Group, Inc. (984.10M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than KalVista Pharmaceuticals, Inc. (468.87M), less than Crinetics Pharmaceuticals, Inc. (4.93B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Viridian Therapeutics, Inc. (1.42B), less than Gracell Biotechnologies Inc. (5.61B), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Design Therapeutics, Inc. (290.40M), greater than Erasca, Inc. (747.42M), less than Cogent Biosciences, Inc. (929.30M), greater than Larimar Therapeutics, Inc. (363.34M), less than Kiniksa Pharmaceuticals, Ltd. (1.45B), less than Day One Biopharmaceuticals, Inc. (963.46M), greater than Inozyme Pharma, Inc. (202.73M), greater than Zentalis Pharmaceuticals, Inc. (229.32M), less than Syndax Pharmaceuticals, Inc. (1.24B),

Build a custom stock screener for Kura Oncology, Inc. (KURA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kura Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kura Oncology, Inc. (KURA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kura Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.